

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1.-13. (Canceled).

14. (Currently Amended) A particulate composition comprising;

a) at least 60% of dioleoyl phosphatidyl ethanolamine (DOPE); and

b) 1 to 40% of Polysorbate 80 (P80),

wherein all parts are by weight relative to the sum of the weights of a+b,

wherein a and b form the total amphiphilic components, and

wherein the composition comprises non-lamellar particles or forms non-lamellar particles when contacted with an aqueous fluid.

15. (Previously Presented) A particulate composition of claim 14 comprising an amphiphilic carrier formulation consisting of;

a) at least 60% of dioleoyl phosphatidyl ethanolamine (DOPE);

b) 1 to 40% of Polysorbate 80 (P80);

c) optionally a solvent;

wherein all parts are by weight relative to the sum of the weights of a+b and wherein the composition comprises non-lamellar particles or forms non-lamellar particles when contacted with an aqueous fluid and wherein the carrier formulation exhibits no toxicity in rats at a level of up to at least 1000 mg of components a+b per kg of subject.

16. (Currently Amended) A particulate composition of claim 14 comprising an amphiphilic carrier formulation consisting of;

a) at least 60% of dioleoyl phosphatidyl ethanolamine (DOPE);

b) 1 to 40% of Polysorbate 80(P80);

c) optionally a solvent;

wherein all parts are by weight relative to the sum of the weights of a+b and wherein the composition comprises non-lamellar particles or forms non-lamellar particles when contacted with an aqueous fluid and wherein the carrier formulation exhibits no pyrogenicity when dosed parenterally in rabbits at a level of up to at least 5 ml of a 5% dispersion of components a+b per kg of subject.

17. (Previously Presented) A composition as claimed in claim 14 additionally comprising at least one active agent.

18. (Previously Presented) A composition as claimed in claim 14 comprising at least 50% non-lamellar particles.

19. (Previously Presented) A composition as claimed in claim 14 which forms at least 50% non-lamellar particles upon contact with an aqueous fluid.

20. (Previously Presented) A composition as claimed in claim 19 wherein said aqueous fluid is a body fluid.

21. (Previously Presented) A composition as claimed in claim 14 wherein said particles have an average particle size of 10 to 150  $\mu\text{m}$ .

22. (Previously Presented) A composition as claimed in claim 14 wherein said particles are colloidal.

23. (Previously Presented) A composition as claimed in claim 22 wherein said particles are stable in terms of phase behavior and particle size to storage at room temperature for at least 10 days.

24. (Previously Presented) A composition as claimed in claim 14 in the form of a dry powder.

25. (Previously Presented) A pharmaceutical formulation comprising a composition as claimed in claim 14.

26. (Previously Presented) A formulation as claimed in claim 25 further comprising at least one pharmaceutically tolerable carrier or excipient.

27. (Previously Presented) The composition of claim 14 comprising;

a) 60 to 95% of dioleoyl phosphatidyl ethanolamine (DOPE); and

b) 4 to 40% of Polysorbate 80 (P80)

wherein all parts are by weight relative to the sum of the weights of a+b.

28. (Previously Presented) The composition of claim 15 comprising;

a) 60 to 95% of dioleoyl phosphatidyl ethanolamine (DOPE); and

b) 4 to 40% of Polysorbate 80 (P80)

wherein all parts are by weight relative to the sum of the weights of a+b.

29. (Previously Presented) The composition of claim 16 comprising;

a) 60 to 95% of dioleoyl phosphatidyl ethanolamine (DOPE); and

b) 4 to 40% of Polysorbate 80 (P80)

wherein all parts are by weight relative to the sum of the weights of a+b.